Article
Mirati lung cancer data disappoint, shares fall 21%
Rating:
0.0
Views:
63
Likes:
1
Library:
1
An experimental Mirati Therapeutics Inc drug that targets a specific genetic mutation shrank tumors in 44% of advanced lung cancer patients in clinical trials, but also caused serious side effects in 43% of them, the company said on Thursday.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value